A clinical study reported that semaglutide, a GLP‑1 receptor agonist, reduces progression of kidney disease in patients with type 2 diabetes and chronic kidney disease. Researchers Alemu, Narasimhan, and Alexander presented results showing slower decline in renal function among treated patients, indicating a potential disease‑modifying effect beyond glycemic control. The findings were published in the Journal of General Internal Medicine and may influence nephrology and endocrinology practice. Clinicians should note the study population and dosing when interpreting applicability.